ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
KMT5a-Mediated IRF3 Stabilization Enhances Macrophage Chemotaxis and Renal Fibrosis Progression.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
While the histone lysine methyltransferase (KMT) family responsible for posttranslational modification has been reported to regulate multiple diseases progression like tumor and cardiovascular disease, its role in renal fibrosis progression is not completely understood. Here, via TGF-β-treated HK-2 cells and an in vivo unilateral ureteral obstruction mice model, the histone lysine methyltransferase family was screened and the upregulated expression of KMT5a was identified in these renal fibrosis models. Interference assays using lentivirus transfection in HK-2 cells and transgenic mice displayed that KMT5a silencing in HK-2 cells impeded macrophage chemotaxis. Moreover, in vivo, transgenic KMT5a knockout inhibited macrophage infiltration, which contributed to the suppression of renal fibrosis progression. Mechanistically, by immunoprecipitation assays and mass spectrometry, we discovered that KMT5a could interact with and stabilize the transcription factor IRF3 to regulate macrophage chemotaxis and infiltration in renal tissues, which accelerated renal fibrosis progression. Notably, we confirmed that a small molecular inhibitor of KMT5a, UNC0379, reduced IRF3 protein levels and macrophage chemotaxis, thus suppressing renal fibrosis, in vitro and in vivo. Therefore, this study presented KMT5a as a mediator of renal fibrosis progression, an effect that was reversed by the KMT5a inhibitor UNC0379, which provided evidence of a novel target and potential drug for inhibiting renal fibrosis progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.